Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Agarwal's Health Care delivered a strong Q3 FY26 with revenue from operations growing 23% YoY to ₹530 crore, driven by volume and value growth. EBITDA grew 21.3% YoY to ₹155 crore with margins stable at 28.4%, while PAT surged 55% YoY to ₹44 crore aided by lower finance costs. Surgical volumes grew 11.6% YoY, with high-end cataract procedures rising to 28% of cataract revenue and robotic cataract surgeries up 83% YoY. The company added 38 new facilities in 9M FY26 and plans 16 more in Q4, targeting 55-60 annual additions. Management reiterated confidence in meeting full-year guidance. Key risk: slower-than-expected ramp-up in newer geographies like Delhi and Ethiopia could pressure near-term margins.
डॉ. अग्रवाल हेल्थ केयर ने Q3 FY26 में मजबूत प्रदर्शन किया। कंपनी की कमाई पिछले साल से 23% बढ़कर ₹530 करोड़ हो गई, जो ज्यादा मरीजों और बेहतर सेवाओं से आई। मुनाफा (EBITDA) 21.3% बढ़कर ₹155 करोड़ रहा, और शुद्ध मुनाफा (PAT) 55% बढ़कर ₹44 करोड़ हो गया, क्योंकि कर्ज पर ब्याज कम हुआ। आंखों के ऑपरेशन 11.6% बढ़े, और महंगे मोतियाबिंद ऑपरेशनों की हिस्सेदारी 28% तक पहुंच गई। रोबोटिक सर्जरी 83% बढ़ी। कंपनी ने 9 महीनों में 38 नए केंद्र खोले और तिमाही में 16 और खोलने की योजना है। प्रबंधन को पूरे साल के लक्ष्य पूरे करने का भरोसा है। जोखिम: दिल्ली और इथियोपिया जैसी नई जगहों पर धीमी शुरुआत से मुनाफा कम हो सकता है।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Slower ramp-up in new geographies
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Total surgeries (9M FY26)
238,283
+11.6% YoY
Total surgeries performed in the first nine months, driven by cataract and refractive procedures.
High-end cataract share
28%
+340bps YoY
High-end cataract procedures as a percentage of total cataract revenue, up from 24.6% in FY25.
Robotic cataract surgeries (9M FY26)
4,400
+83% YoY
Robotic cataract surgeries grew sharply, reflecting technology adoption and premiumization.
Daily patient walk-ins
10,000
+25% YoY
Average daily footfall across facilities, up from ~8,000 in the previous fiscal year.
What Changed vs Last Quarter
NEW
Annual facility additions of 55-60
Management guided to add 55-60 new facilities every year, increasing network size by ~20% annually.
NEW
Q4 FY26 facility additions: 16 centers
Plan to launch 16 new centers in Q4 FY26, including 11 surgical centers across south, west, and north regions.
NEW
Merger completion by Q3-Q4 FY27
The merger process with subsidiaries is expected to be completed by Q3 or Q4 of FY27, pending regulatory approvals.
UPDATED
Capex guidance of ₹310 crore for FY26
Management committed ₹310 crore capex for FY26; ₹275 crore already spent in 9M FY26.
DROPPED
42 new facilities in next three quarters
Management targets launching 42 new facilities across India, with 23 in the south, 9 in the west, 5 in the north, and 5 in the east.
DROPPED
ROIC improvement of 1-1.5% in FY26
Management expects ROIC to increase by about 1 to 1.5 percentage points in FY26 from ~16% in FY25.
DROPPED
Merger of subsidiary within 1-1.5 years
Management aims to complete the merger of the listed subsidiary with the parent within the next 1 to 1.5 years, with more clarity in coming weeks.
NEW RISK
Slower ramp-up in new geographies
New facilities in non-core markets like Delhi and Ethiopia may take 15-18 months to break even, potentially pressuring near-term margins.
NEW RISK
Revenue per facility decline in newer regions
Analyst noted a drop in revenue per facility in the east region; management attributed it to early-stage facilities, but sustained underperformance could signal competitive pressure.
NEW RISK
Labor code implementation risk
New labor codes could increase employee costs; management assessed impact as not material currently but continues to monitor.
RISK GONE
Delhi NCR expansion execution risk
The new Delhi facility faced a 6-9 month delay due to floods. While now operational, scaling up in a competitive market may take time and could impact near-term profitability.
RISK GONE
Subsidiary merger timeline uncertainty
Management provided a broad timeline of 1-1.5 years for the merger but noted it is still under evaluation. Delays could affect corporate structure and minority shareholder returns.
RISK GONE
Geopolitical disruption impact
Operations in northern India were briefly impacted by the Bahalgam attack and Operation Hindu, highlighting vulnerability to regional disruptions.
Fast read
Guidance and risk preview
Management guided to add 55-60 new facilities every year, increasing network size by ~20% annually.
New facilities in non-core markets like Delhi and Ethiopia may take 15-18 months to break even, potentially pressuring near-term margins.
View Risks →